BBS Bioactive (Finland) Today
| BONEH Stock | EUR 0.07 0 4.23% |
Performance0 of 100
| Odds Of DistressOver 63
|
BBS Bioactive is trading at 0.068 as of the 13th of December 2024. This is a 4.23 percent decrease since the beginning of the trading day. The stock's open price was 0.071. BBS Bioactive has more than 63 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 24th of December 2022 and ending today, the 13th of December 2024. Click here to learn more.
BBS-Bioactive Bone Substitutes Oyj, a biomedical technology company, develops, designs, manufactures, and sells bioactive medical devices and implants for orthopedic surgery in Finland. The company was founded in 2003 and is headquartered in Oulu, Finland. The company has 9.67 M outstanding shares. More on BBS Bioactive Bone Substitutes
Moving together with BBS Stock
Moving against BBS Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
BBS Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BBS Bioactive's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BBS Bioactive or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Medical Devices, Healthcare (View all Sectors) |
BBS Bioactive Bone Substitutes (BONEH) is traded on Helsinki Exchange in Finland and employs 21 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BBS Bioactive's market, we take the total number of its shares issued and multiply it by BBS Bioactive's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BBS Bioactive Bone operates under Healthcare sector and is part of Medical Devices industry. The entity has 9.67 M outstanding shares.
BBS Bioactive Bone Substitutes has accumulated about 3.44 M in cash with (2.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.52, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check BBS Bioactive Probability Of Bankruptcy
Ownership AllocationThe market capitalization of BBS Bioactive Bone is €12.23 Million. BBS Bioactive Bone retains considerable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the entity is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check BBS Ownership Details
BBS Bioactive Bone Risk Profiles
Although BBS Bioactive's alpha and beta are two of the key measurements used to evaluate BBS Bioactive's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 4.85 | |||
| Standard Deviation | 9.04 | |||
| Variance | 81.71 | |||
| Risk Adjusted Performance | (0.13) |
BBS Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in BBS Bioactive without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
BBS Bioactive Corporate Management
Elected by the shareholders, the BBS Bioactive's board of directors comprises two types of representatives: BBS Bioactive inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BBS. The board's role is to monitor BBS Bioactive's management team and ensure that shareholders' interests are well served. BBS Bioactive's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BBS Bioactive's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jussi Jukka | Head Production | Profile | |
| Jari Msc | Chief Officer | Profile | |
| Paul Watkins | Chief Board | Profile | |
| Pr Kangasniemi | Chief Officer | Profile |
Other Information on Investing in BBS Stock
BBS Bioactive financial ratios help investors to determine whether BBS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BBS with respect to the benefits of owning BBS Bioactive security.